blue 3D waveform render

Investors

Welcome to the iCAD Investors page.

iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com

2024 Investor Deck

Press Releases

March 12, 2024

iCAD Announces Fiscal Fourth Quarter and Full-Year 2023

Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-year Full-Year Operating Cash Flow ($5) million vs. ($12.8) million prior year Year ending cash balance of $21.7M NASHUA, N.H. – March 12, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical…

February 28, 2024

iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings

NASHUA, N.H. – Feb. 28, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, will highlight scientific presentations, including an award-winning poster at the European Congress of Radiology (ECR) annual…

February 27, 2024

iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

NASHUA, NH., February 27, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will release financial results for the fourth quarter and full year…

Recent Events & Earning Calls

009 – Graph Created with Sketch.

Investor Relations

iCAD Investor Relations
ir@icadmed.com
Megaphone

Media Inquiries